{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Pediatric+ALL&page=2", "query": { "condition": "B-Cell Pediatric ALL", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-Cell+Pediatric+ALL&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T18:32:06.724Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05206357", "title": "Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "Epcoritamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 17, "start_date": "2022-10-04", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-06-10T18:32:06.724Z", "location_count": 8, "location_summary": "Palo Alto, California • Miami, Florida • Valhalla, New York + 5 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Valhalla", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05206357" }, { "nct_id": "NCT07313592", "title": "Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "ChromoSeq® assay testing", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 60, "start_date": "2026-06-03", "completion_date": "2028-07-15", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-10T18:32:06.724Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07313592" }, { "nct_id": "NCT03860844", "title": "Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Dexamethasone or equivalent", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Liposomal daunorubicin", "type": "DRUG" }, { "name": "Daunorubicin (nonliposomal)", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Filgrastim or equivalent", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Pegaspargase (PEG) Asparaginase", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "L - Asparginase", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "L - Asparaginase (Erwinase)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "28 Days", "maximum_age": "17 Years", "sex": "ALL", "summary": "28 Days to 17 Years" }, "enrollment_count": 67, "start_date": "2019-08-06", "completion_date": "2023-05-26", "has_results": true, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-06-10T18:32:06.724Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Dallas, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03860844" }, { "nct_id": "NCT00118326", "title": "Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Cancer", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Neuroblastoma", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": null, "start_date": "2003-08", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2010-05-14", "last_synced_at": "2026-06-10T18:32:06.724Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Seattle, Washington", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118326" }, { "nct_id": "NCT02227108", "title": "Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Pediatric ALL" ], "interventions": [ { "name": "Moxetumomab Pasudotox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Months to 18 Years" }, "enrollment_count": 37, "start_date": "2014-08", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-04-06", "last_synced_at": "2026-06-10T18:32:06.724Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02227108" }, { "nct_id": "NCT05645718", "title": "Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Inotuzumab ozogamicin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 27, "start_date": "2023-07-14", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-06-10T18:32:06.724Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05645718" }, { "nct_id": "NCT05544019", "title": "Study of SGR-1505 in Mature B-Cell Neoplasms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mature B-Cell Neoplasm", "Non Hodgkin Lymphoma", "DLBCL", "Waldenstrom Macroglobulinemia", "MALT Lymphoma", "Follicular Lymphoma", "Pediatric-Type Follicular Lymphoma", "IRF4 Gene Rearrangement", "EBV-Positive DLBCL, Nos", "Burkitt Lymphoma", "Plasmablastic Lymphoma", "High-grade B-cell Lymphoma", "Primary Cutaneous Follicle Center Lymphoma", "Primary Effusion Lymphoma", "Mantle Cell Lymphoma", "DLBCL Germinal Center B-Cell Type", "Primary Mediastinal Large B Cell Lymphoma", "T-Cell/Histiocyte Rich Lymphoma", "ALK-Positive Large B-Cell Lymphoma", "Primary Cutaneous Diffuse Large B-Cell Lymphoma", "Splenic Marginal Zone Lymphoma", "Chronic Lymphocytic Leukemia", "Nodal Marginal Zone Lymphoma", "HHV8-Positive DLBCL, Nos", "Lymphoplasmacytic Lymphoma", "Duodenal-Type Follicular Lymphoma" ], "interventions": [ { "name": "SGR-1505", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Schrödinger, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2023-04-10", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-06-10T18:32:06.724Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Newark", "state": "Delaware" }, { "city": "Pompano Beach", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05544019" }, { "nct_id": "NCT05480449", "title": "Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B Cell Acute Lymphoblastic Leukemia (B-ALL)", "B Lineage Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stephan Grupp MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "0 Years to 29 Years" }, "enrollment_count": 115, "start_date": "2022-09-20", "completion_date": "2029-09-20", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-10T18:32:06.724Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05480449" }, { "nct_id": "NCT00365768", "title": "Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Leukemia", "Lymphoma", "Neurotoxicity", "Peripheral Neuropathy", "Sarcoma" ], "interventions": [ { "name": "Glutamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "5 Years to 21 Years" }, "enrollment_count": 56, "start_date": "2004-10", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2016-09-09", "last_synced_at": "2026-06-10T18:32:06.724Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00365768" }, { "nct_id": "NCT03876769", "title": "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "CTL019", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 121, "start_date": "2019-06-24", "completion_date": "2027-10-19", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-10T18:32:06.724Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03876769" } ] }